The global syndromic testing market is expected to witness a significant growth rate of more than 7% during the forecast period. The global syndromic testing market is a rapidly growing segment of the healthcare industry, driven by the increasing demand for accurate and rapid diagnostic tests. These tests are used for the diagnosis of various infectious diseases, including respiratory infections, sexually transmitted infections, and gastrointestinal infections.
The market is driven by several key drivers such as the increasing prevalence of infectious diseases, rising demand for rapid diagnostics tests, and technological advancements in molecular diagnostics. Moreover, increasing government incentives and funding for research coupled with growing awareness about the benefits of early diagnosis are also expected to drive the demand for the syndromic testing market across the globe.
The respiratory panel is expected to dominate the market owing to the high prevalence of respiratory infections
The respiratory panel segment is expected to dominate the global syndromic testing market, accounting for the largest market share. This is due to the high prevalence of respiratory infections, such as flu, pneumonia, and bronchitis, which are responsible for a significant proportion of hospital admissions and healthcare costs globally. In addition, respiratory panel tests are widely available and are used by healthcare providers for the diagnosis of multiple respiratory pathogens simultaneously.
However, the gastrointestinal panel segment is expected to grow at a strong CAGR during the forecast period. This is attributed to the increasing incidence of gastrointestinal infections, such as norovirus, rotavirus, and Clostridium difficile, which cause severe diarrhea and vomiting. Furthermore, gastrointestinal panel tests are used for the rapid and accurate diagnosis of these infections, and their demand is expected to increase in the coming years due to their efficiency and reliability.
Advanced diagnostic technologies coupled with the well-established healthcare sector helped North America to dominate the global syndromic testing market
North America is anticipated to dominate the syndromic testing market and accounted for the major market share due to the presence of well-established healthcare infrastructure, advanced diagnostic technologies, and high healthcare expenditure. Europe is also one of the prominent regions for syndromic testing with significant growth potential due to the increasing adoption of molecular diagnostic technologies and the rising incidence of infectious diseases.
The Asia-Pacific region is expected to witness the uppermost growth rate in the coming years, driven by factors such as increasing healthcare expenditure, rising awareness about early diagnosis, and the growing prevalence of infectious diseases. Latin America and the Middle East & Africa are also expected to witness significant growth in the syndromic testing market in the coming years. The growing demand for rapid diagnostic tests, increasing investments in healthcare infrastructure, and rising awareness about infectious diseases are some of the key drivers of market growth in these regions.
Market Structure and Competitive Landscape
The global syndromic testing market is fragmented in nature with the presence of various players in the market. Some of the prominent players operating in the global syndromic testing market include BioFire Diagnostics, Luminex Corporation, Alere Inc, Becton, Dickinson and Company, Cepheid Inc., GenMark Diagnostics Inc., Hologic Inc., Quidel Corporation, Siemens Healthineers, and Thermo Fisher Scientific Inc. among others. These players adopt various strategies including mergers and acquisitions, partnerships and collaborations which directly results in propelling the growth of the global syndromic testing market.
Key Market Segmentation
RationalStat has segmented the global syndromic testing market on the basis of product / services, panels type, disease, end use, and region.
- By Product / Services
- Reagents & Consumables
- Instruments, Software & Accessories
- Services
- By Panels Type
- Respiratory Panel
- GI-Enteric Panel
- Sexually Transmitted Disease Panel
- Blood-Sepsis Panel
- Others (Meningitis Panel, etc.)
- By Disease
- Respiratory Infection
- Gastroenteritis
- Sexually Transmitted Infections
- Sepsis
- Others (Meningitis, etc.)
- By End User
- Hospitals
- Diagnostic labs
- Others (ASCs etc.)
- By Region
- North America
- US
- Canada
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Western Europe
- Germany
- UK
- France
- Spain
- Italy
- Benelux
- Nordic
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Rest of Eastern Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- ASEAN (Indonesia, Vietnam, Malaysia, etc.)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- South Africa
- Turkey
- Rest of the Middle East & Africa
- North America
Research Methodology
RationalStat has developed a state-of-the-art research methodology to crunch numbers and provide the best possible real-time insights to clients. We combine a varied range of industry experience, data analytics, and experts’ viewpoint to create a research methodology for market sizing and forecasting.
RationalStat combines a mix of secondary sources as well as primary research to assess the market size and develop a forecast. Key steps involved in accurately deriving the market numbers are:
- Defining the problem by understanding the type of market and data required by the client.
- Data gathering and collection through relevant paid databases, publicly available sources, company reports, annual reports, surveys, and interviews.
- Formulating a hypothesis to create market numbers, forecast, influencing factors, and their relevance.
- Evaluating and analyzing the data by referring to data sources utilized and leveraged.
- Validating, interpreting, and finalizing the data by combining the details gathered from primary and secondary sources with the help of experienced analysts.
Secondary Sources
- Annual reports, company filings, investor presentations, product catalogs, and company documents
- Industry and market-related documents available in the public domain
- Paid database including Bloomberg, Factiva, S&P Capital IQ, FactSet, Refinitiv Eikon, ICIS, EUWID, Thomson Reuters, among others
- Whitepapers, research papers, and industry blogs.
Why Buy this Report?
The report is intended for Syndromic testing providers, healthcare industry, government organizations, educational organizations, regulatory agencies, and market research firms, among others. The report provides an in-depth analysis of market size, consumption patterns, ongoing market trends and challenges, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights to clients to find the right answers to their business questions.
Frequently Asked Questions (FAQs)
The global syndromic testing market is expected to grow at a CAGR of over 7.2% during the forecast period 2022-2028.
North America is dominating the global syndromic testing market in 2022.
Rising demand for rapid diagnostics tests is the key driver of the global syndromic testing market.
Major companies operating in the global syndromic testing market include BioFire Diagnostics, Luminex Corporation, Alere Inc, Becton, Dickinson and Company, Cepheid Inc., GenMark Diagnostics Inc., Hologic Inc., Quidel Corporation, Siemens Healthineers, and Thermo Fisher Scientific Inc, etc.